BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30737098)

  • 1. Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status.
    Zihui Yong Z; Ching GTH; Ching MTC
    J Surg Res; 2020 Feb; 246():325-334. PubMed ID: 30737098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
    Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
    Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
    Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
    Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
    Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
    Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
    BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
    Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
    J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
    Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
    J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
    Atreya CE; Greene C; McWhirter RM; Ikram NS; Allen IE; Van Loon K; Venook AP; Yeh BM; Behr SC
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1536-1543. PubMed ID: 27956538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study.
    Byun JH; Ahn JB; Kim SY; Kang JH; Zang DY; Kang SY; Kang MJ; Shim BY; Baek SK; Kim BS; Lee KH; Lee SI; Cho SH; Sohn BS; Kim S; Hwang IG; Nam EM; Seo BG; Oh SC; Lee MA; Lee SC; Hong JH; Park YS
    Korean J Intern Med; 2019 Jan; 34(1):165-177. PubMed ID: 29172407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases.
    Allievi N; Goffredo P; Utria AF; Pisano M; Poiasina E; Lucianetti A; Zhou P; Hassan I
    Chin Clin Oncol; 2019 Oct; 8(5):46. PubMed ID: 31500429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?
    Allard MA; Saffroy R; de la Maisonneuve PB; Ricca L; Bosselut N; Hamelin J; Lecorche E; Bejarano MA; Innominato P; Sebagh M; Adam R; Morère JF; Lemoine A
    Target Oncol; 2015 Sep; 10(3):415-21. PubMed ID: 25420993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases.
    Goffredo P; Utria AF; Beck AC; Chun YS; Howe JR; Weigel RJ; Vauthey JN; Hassan I
    J Gastrointest Surg; 2019 Oct; 23(10):1957-1963. PubMed ID: 30276588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer.
    Yarom N; Gresham G; Boame N; Jonker D
    Clin Colorectal Cancer; 2019 Dec; 18(4):e309-e315. PubMed ID: 31547963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.
    Margonis GA; Amini N; Buettner S; Kim Y; Wang J; Andreatos N; Wagner D; Sasaki K; Beer A; Kamphues C; Morioka D; Løes IM; Imai K; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Burkhart R; Endo I; Baba H; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    Ann Surg; 2021 Jun; 273(6):1165-1172. PubMed ID: 31389831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
    Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V
    Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.
    Cejas P; López-Gómez M; Aguayo C; Madero R; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Larrauri J; López R; Casado E; Gonzalez-Barón M; Feliu J
    PLoS One; 2009 Dec; 4(12):e8199. PubMed ID: 20020061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS.
    Margalit O; Shacham-Shmueli E; Lawrence YR; Yang YX; Reiss KA; Golan T; Mamtani R; Halpern N; Aderka D; Giantonio B; Boursi B
    Clin Colorectal Cancer; 2019 Sep; 18(3):e300-e307. PubMed ID: 31324478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.